• 1
    Brunner FP, Landais P, Selwood NH. Malignancies after renal transplantation: the EDTA-ERA registry experience. European dialysis and transplantation association–European Renal Association. Nephrol Dial Transplant 1995; 10: 7480.
  • 2
    Stewart T, Tsai S-CJ, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995; 346: 796798.
  • 3
    Sheil AGR. Cancer report. In: Disney, APS, ed. The Twentieth Report Australia and New Zealand Dialysis and Transplant Registry 1997. Adelaide , South Australia : ANZDATA Registry, 1997: 138146.
  • 4
    Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000; 355: 18861887.
  • 5
    Adami J, Gabel H, Lindelof B et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 12211227.
  • 6
    United States Renal Data System. USRDS 2003 Annual Data Report. Atas of End-Stage Renal Disease in the United States. Bethesda, MD : National Institutes of Health. National Institute of Diabetes and Digestive Kidney Diseases , 2003.
  • 7
    Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14: 270277.
  • 8
    United States Cancer Statistics Working Group. United States Cancer Statistics: 1999 Incidence. Atlanta , GA : Department of Health and Human Services. Centers for Disease Control and Prevention and National Cancer Insitute , 2002.
  • 9
    US Preventative Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann Intern Med 2002; 137: 915916.
  • 10
    US Preventative Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002; 137: 129131.
  • 11
    US Preventative Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med 2002; 137: 344346.
  • 12
    The Tobacco Use Dependence Clinical Practice Guideline Panel, Staff, Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA 2000; 283: 32443254.
  • 13
    Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant 2003; 3: 619625.
  • 14
    Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2003; 4: 222230.
  • 15
    Bustami RT, Ojo AO, Wolfe RA et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 8793.
  • 16
    Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917926.
  • 17
    Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 9399.
  • 18
    Jong-Tieben LM, Berkhout RJ, Ter Schegget J et al. The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 2000; 69: 4449.
  • 19
    Harwood CA, Surentheran T, McGregor JM et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000; 61: 289297.
  • 20
    Nobbenhuis MA, Walboomers JM, Helmerhorst TJ et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 2025.
  • 21
    Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 6373.
  • 22
    Moosa MR, Treurnicht FK, Van Rensburg EJ, Schneider JW, Jordaan HF, Engelbrecht S. Detection and subtyping of human herpesvirus-8 in renal transplant patients before and after remission of Kaposi's sarcoma. Transplantation 1998; 66: 214218.
  • 23
    Farge D, Lebbe C, Marjanovic Z et al. Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d'Ile de France (GCIF). Transplantation 1999; 67: 12361242.
  • 24
    Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001; 28: 441449.
  • 25
    El Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72S78.
  • 26
    Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 15171525.
  • 27
    Meijer E, Dekker AW, Weersink AJ, Rozenberg-Arska M, Verdonck LF. Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants. Br J Haematol 2002; 119: 596607.
  • 28
    Stewart JH, Buccianti G, Agodoa L et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003; 14: 197207.
  • 29
    Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11: 753759.